View Author
patient myeloma bortezomib thalidomide therapy study treatment dexamethasone response blood trial survival cancer university lenalidomide disease group combination phase regimen factor hospital signi serum month neuropathy result melphalan table agent grade transplantation hematology randomized department analysis high-dose novel agents signi ficantly progression chemotherapy outcome oncol novel myeloma patients prednisone ef ficacy cell transplantation induction cycle cyclophosphamide j clin oncol maintenance doxorubicin chain leukemia number palumbo autologou incidence celgene light effect marrow guideline erasmus mc neutropenia protein level response rate oncology high-dose therapy event high-dose dexamethasone risk factors institute center transplant reduction ficantly
10 Most Recent Publications
|
How to manage neutropenia in multiple myeloma
(Article)
Palumbo, A. Bladé, J. Spencer, A. Sonneveld, P. San Miguel, J-F. Boccadoro, M. Palladino, C. Davies, F. Dimopoulos, M.A. Dmoszynska, A. Einsele, H. Moreau, P. Sezer, O. |
2012-02-01
|
|
Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)
(Article)
Palumbo, A. Bringhen, S. Zweegman, S. Terpos, E. Davies, F. Driessen, C. Gimsing, P. Gramatzki, M. Hajek, R. Johnsen, H.E. Da Costa, F.L. Sezer, O. Ludwig, H. Spencer, A. Beksaç, M. Morgan, G. Einsele, H. San Miguel, J. Sonneveld, P. Dimopoulos, M.A. Bladé, J. Mateos, M.V. Rosiñol, L. Boccadoro, M. Cavo, M. Lokhorst, H.M. |
2011-10-27
|
|
International myeloma working group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
(Article)
Cavo, M. Rajkumar, S.V. Sonneveld, P. Boccadoro, M. Anderson, K.C. Richardson, P.G. Bensinger, W. Johnsen, H.E. Kroeger, N. Gahrton, G. Bergsagel, P.L. Vesole, D.H. Palumbo, A. Einsele, H. Jagannath, S. Niesvizky, R. Durie, B.G.M. Miguel, J.S. Lonial, S. Moreau, P. Orlowski, R.Z. Bladé, J. Sezer, O. Ludwig, H. Dimopoulos, M.A. Attal, M. |
2011-06-09
|
|
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: Analysis of 1175 patients
(Article)
Gay, F. Larocca, A. Petrucci, M. Nozzoli, C. Patriarca, F. Offidani, M. Ria, R. Omedè, P. Bruno, B. Passera, R. Musto, P. Boccadoro, M. Wijermans, P. Sonneveld, P. Palumbo, A. Cavallo, F. Rossi, D. Schaafsma, R. Genuardi, M. Romano, A. Liberati, A.M. Siniscalchi, A. |
2011-03-17
|
|
European Myeloma Network: The 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma
(Article)
Engelhardt, M. Udi, J. Driessen, C. Patriarca, F. Gramatzki, M. Terpos, E. Sezer, O. Kropff, M. Straka, C. Johnsen, H.E. Waage, A. Boegsted, M. Kleber, M. Lokhorst, H.M. Hjek, R. Morgan, G. Boccadoro, M. Ludwig, H. Cavo, M. Polliack, A. Sonneveld, P. Einsele, H. Palumbo, A. Spencer, A. Rocci, A. Knop, S. Bruno, B. Bringhen, S. Pérez-Simn, J.A. Zweegman, S. |
2010-11-01
|
|
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
(Article)
Kyle, R. Durie, B.G.M. San Miguel, J-F. Avet-Loiseau, H. Hajek, R. Chen, W. Anderson, K.C. Ludwig, H. Sonneveld, P. Pavlovsky, S. Palumbo, A. Richardson, P.G. Rajkumar, S.V. Barlogie, B. Greipp, P. Vescio, R. Turesson, I. Westin, J. Boccadoro, M. Landgren, O. Bladé, J. Merlini, G. Kröger, N. Einsele, H. Vesole, D. Dimopoulos, M.A. |
2010-04-22
|
|
Current multiple myeloma treatment strategies with novel agents: A European perspective
(Article)
Ludwig, H. Beksac, M. Goldschmidt, H. Harousseau, J-L. Hess, U. Ketterer, N. Kropff, M. Mendeleeva, L. Morgan, G. Palumbo, A. Plesner, T. San Miguel, J-F. Bladé, J. Shpilberg, O. Sondergeld, P. Sonneveld, P. Zweegman, S. Boccadoro, M. Cavenagh, J. Cavo, M. Dimopoulos, M.A. Drach, J. Einsele, H. Facon, T. |
2010-02-05
|
|
The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network
(Article)
Terpos, E. Sezer, O. Dimopoulos, M.A. Facon, T. Macro, M. Waage, A. Sonneveld, P. Croucher, P.I. Garcia-Sanz, R. Boccadoro, M. San Miguel, J-F. Ashcroft, J. Blade, J. Cavo, M. Delforge, M. |
2009-10-01
|
|
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
(Article)
Giralt, S. Stadtmauer, E.A. Merlini, G. San Miguel, J. Ludwig, H. Hajek, R. Jagannath, S. Blade, J. Lonial, S. Dimopoulos, M.A. Einsele, H. Barlogie, B. Harousseau, J-L. Anderson, K.C. Gertz, M. Attal, M. Tosi, P. Sonneveld, P. Boccadoro, M. Morgan, G. Sezer, O. Mateos, M.V. Cavo, M. Palumbo, A. Joshua, D. Turesson, I. Chen, W. Shimizu, K. Powles, R. Richardson, P.G. Niesvizky, R. Rajkumar, S.V. Durie, B.G.M. Bensinger, W. Comenzo, R.L. Kumar, S. Munshi, N.C. Dispenzieri, A. Kyle, R. |
2009-06-26
|
|
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
(Article)
Palumbo, A. Sezer, O. Kumar, S. Hajek, R. Giralt, S. Bringhen, S. Anderson, K.C. Richardson, P.G. Cavo, M. Davies, F. Bladé, J. Einsele, H. Kyle, R. Dimopoulos, M.A. Spencer, A. Dispenzieri, A. Reiman, T. Shimizu, K. Lee, J.H. Attal, M. Boccadoro, M. Mateos, M.V. Chen, W. Miguel, J.S. Ludwig, H. Joshua, D. Chim, J. Hungria, V. Turesson, I. Durie, B.G.M. Lonial, S. Orlowski, R.Z. Moreau, P. Niesvizky, R. Morgan, G. Comenzo, R.L. Sonneveld, P. |
2009-06-08
|
